

DAFTAR PUSTAKA

1. Amin M, Yunus F, Antariksa B. Definisi. In: Amin M, Yunus F, Antariksa B, Djajalaksana S, Wiyono W, Sutoyo D, editors. Penyakit paru obstruktif kronik (PPOK) diagnosis dan penatalaksanaan. 1st ed. Jakarta: UI Press; 2016. p. 3–6.
2. Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *Eur Respir J*. 2023;61(4).
3. Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. *East Mediterr Heal J = La Rev sante la Mediterr Orient = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2019;25(1):47–57.
4. World Health Organization. Chronic obstructive pulmonary disease (COPD) [Internet]. Available from: [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd))
5. Cheng S-L, Lin C-H. COPD Guidelines in the Asia-Pacific Regions: Similarities and Differences. *Diagnostics (Basel, Switzerland)*. 2021;11(7).
6. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Respir Med*. 2017;5(9):691–706.
7. Patil S, Toshniwal S, Gondhali G. Small airway disease: A new “phenotype” of obstructive airway disease. *Ann Med Sci Res*. 2023;2(1). Available from: https://journals.lww.com/amr/fulltext/2023/01000/small_airway_disease__a_new__phenotype__of.9.aspx
8. Korkmaz C, Demirbas S, Vatansev H, Yildirim E, Teke T, Zamani A. Effects of comprehensive and intensive pulmonary rehabilitation and nutritional support on quality of life and functional status in patients with chronic obstructive pulmonary disease. *J Int Med Res*.

- 2020;48(4):300060520919567.
9. Gupta R, Ruppel GL, Espiritu JRD. Exercise-Induced Oxygen Desaturation during the 6-Minute Walk Test. *Med Sci (Basel, Switzerland)*. 2020;8(1).
 10. Gao P, Tang F, Liu W, He K, Mo Y. Effect of liuzijue qigong on patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2021;100(41):e27344.
 11. Shi J, Wang R-J, Wang F. Mind–Body Health Technique Liu Zi Jue: Its Creation, Transition, and Formalization. *Sage Open*. 2020;10(2):2158244020927024. Available from: <https://doi.org/10.1177/2158244020927024>
 12. Halpin DMG, Celli BR, Criner GJ, Frith P, López Varela MV, Salvi S, et al. It is time for the world to take COPD seriously: a statement from the GOLD board of directors. *Eur Respir J*. 2019;54(1).
 13. Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. *Am J Respir Crit Care Med*. 2022;206(11):1317–25.
 14. Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. *Eur Respir J*. 2019;54(2).
 15. Hikichi M, Mizumura K, Maruoka S, Gon Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. *J Thorac Dis*. 2019;11(Suppl 17):S2129–40.
 16. Oktaria D, Ningrum MS. Pengaruh Merokok dan Defisiensi Alfa-1 Antitripsin Terhadap Progresivitas Penyakit Paru Obstruktif Kronis (PPOK) dan Emfisema. *Medicine (Baltimore)*. 2017; Available from: <https://api.semanticscholar.org/CorpusID:80002428>
 17. Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. *BMJ*. 2006;332(7550):1142–4.
 18. Higham A, Quinn AM, Cançado JED, Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. *Respir Res*. 2019;20(1):49.
 19. Barnes PJ, Burney PGJ, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, et

- al. Chronic obstructive pulmonary disease. *Nat Rev Dis Prim.* 2015;1:15076.
20. Hadzic S, Wu C-Y, Avdeev S, Weissmann N, Schermuly RT, Kosanovic D. Lung epithelium damage in COPD - An unstoppable pathological event? *Cell Signal.* 2020;68:109540.
 21. McGuinness AJA, Sapey E. Oxidative Stress in COPD: Sources, Markers, and Potential Mechanisms. *J Clin Med.* 2017;6(2).
 22. Bose P, Bathri R, Kumar L, Vijayan VK, Maudar KK. Role of oxidative stress & transient receptor potential in chronic obstructive pulmonary disease. *Indian J Med Res.* 2015;142(3):245–60.
 23. Saunders RM, Biddle M, Amrani Y, Brightling CE. Stressed out - The role of oxidative stress in airway smooth muscle dysfunction in asthma and COPD. *Free Radic Biol Med.* 2022;185:97–119.
 24. Kato A, Hanaoka M. Pathogenesis of COPD (Persistence of Airway Inflammation): Why Does Airway Inflammation Persist After Cessation of Smoking? *Chronic Obstructive Pulmonary Disease: A Systemic Inflammatory Disease.* 2017. p. 57–72.
 25. Sauler M, Bazan IS, Lee PJ. Cell Death in the Lung: The Apoptosis-Necroptosis Axis. *Annu Rev Physiol.* 2019;81:375–402.
 26. Chambers E, Rounds S, Lu Q. Pulmonary Endothelial Cell Apoptosis in Emphysema and Acute Lung Injury. *Adv Anat Embryol Cell Biol.* 2018;228:63–86.
 27. Zheng DJ, Abou Taka M, Heit B. Role of Apoptotic Cell Clearance in Pneumonia and Inflammatory Lung Disease. *Pathog (Basel, Switzerland).* 2021;10(2).
 28. Weinberger SE, Cockrill B, Mandel J. Principles of pulmonary medicine. *Principles of Pulmonary Medicine.* 2018. 1–410 p.
 29. Peng H, Zhou Q, Liu J, Wang Y, Mu K, Zhang L. Endoplasmic reticulum stress: a vital process and potential therapeutic target in chronic obstructive pulmonary disease. *Inflamm Res Off J Eur Histamine Res Soc . [et al].* 2023;72(9):1761–72.
 30. D’Anna SE, Maniscalco M, Cappello F, Carone M, Motta A, Balbi B, et al.

- Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. *Ann Med.* 2021;53(1):135–50.
31. Shah BK, Singh B, Wang Y, Xie S, Wang C. Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment. *Mediators Inflamm.* 2023;2023:8840594.
 32. Li J, Ye Z. The Potential Role and Regulatory Mechanisms of MUC5AC in Chronic Obstructive Pulmonary Disease. *Molecules.* 2020;25(19).
 33. Laghi FAJ, Saad M, Shaikh H. Ultrasound and non-ultrasound imaging techniques in the assessment of diaphragmatic dysfunction. *BMC Pulm Med.* 2021;21(1):85.
 34. Macnee W, Vestbg J, Agusti A. COPD: pathogenesis and natural history. In: Broaddus VC, Mason RJ, Ernst JD, King TE, Lazarus SC, Murray JF, et al., editors. *Murray & Nadel's Textbook of Respiratory Medicine.* 6th ed. Philadelphia: Elsevier Inc.; 2016. p. 751–860.
 35. Sikjær MG, Klitgaard A, Hilberg O, Løkke A. Parental COPD as a Risk Factor for the Development of COPD and Disease Severity in Offspring: A Systematic Scoping Review. *Int J Chron Obstruct Pulmon Dis.* 2022;17:1323–38.
 36. Lee J. Pathogenesis of COPD. In: Lee S, editor. *COPD heterogeneity and personalized treatment.* 1st ed. Berlin: Springer; 2017. p. 35–46.
 37. Craig TJ, Henao MP. Advances in managing COPD related to $\alpha(1)$ - antitrypsin deficiency: An under-recognized genetic disorder. *Allergy.* 2018;73(11):2110–21.
 38. H C, B D, H Z, J BA, H A. Pulmonary Emphysema in Cutis Laxa: A Report of Two Cases. *J Lung Dis Treat.* 2018;04(02):8–10.
 39. Blanco I, Tura-Ceide O, Peinado VI, Barberà JA. Updated Perspectives on Pulmonary Hypertension in COPD. *Int J Chron Obstruct Pulmon Dis.* 2020;15:1315–24.
 40. Clarke SY, Williams MT, Johnston KN, Lee AL. The prevalence and assessment of pain and dyspnoea in acute exacerbations of COPD: A systematic review. *Chron Respir Dis.* 2022;19:14799731221105518.

41. Silverman EK. Genetics of COPD. *Annu Rev Physiol.* 2020;82:413–31.
42. Jonathan S, Damayanti T, Antariksa B. Pathophysiology of Emphysema. *J Respirologi Indones.* 2019;39:60–9.
43. Cao Y, Li P, Wang Y, Liu X, Wu W. Diaphragm Dysfunction and Rehabilitation Strategy in Patients With Chronic Obstructive Pulmonary Disease. *Front Physiol.* 2022;13:872277.
44. Shujaat A, Bajwa AA, Cury JD. Pulmonary Hypertension Secondary to COPD. *Pulm Med.* 2012;2012:203952.
45. Obling N, Rangelov B, Backer V, Hurst JR, Bodtger U. Upper airway symptoms and Small Airways Disease in Chronic Obstructive Pulmonary Disease, COPD. *Respir Med.* 2022;191:106710.
46. Ribeiro S, Cardoso CS, Valério M, Machado J, Costa J, Rodrigues C, et al. Confirmatory Evaluation of the Modified Medical Research Council Questionnaire for Assessment of Dyspnea in Patients with Chronic Obstructive Pulmonary Disease in Portugal. *Acta Med Port.* 2022;35(2):89–93.
47. Lynch DA, Austin JHM, Hogg JC, Grenier PA, Kauczor H-U, Bankier AA, et al. CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. *Radiology.* 2015;277(1):192–205.
48. Rangelov BA, Young AL, Jacob J, Cahn AP, Lee S, Wilson FJ, et al. Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review. *Int J Chron Obstruct Pulmon Dis.* 2020;15:1751–87.
49. Leuzzi G, Galeone C, Taverna F, Suatoni P, Morelli D, Pastorino U. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. *Eur Respir Rev an Off J Eur Respir Soc.* 2017;26(143).
50. Kwon DS, Choi YJ, Kim TH, Byun MK, Cho JH, Kim HJ, et al. FEF(25-75%) Values in Patients with Normal Lung Function Can Predict the Development of Chronic Obstructive Pulmonary Disease. *Int J Chron Obstruct Pulmon Dis.* 2020;15:2913–21.
51. Shenoy SJ. Can FEF25-75 Be Used As a Valid Alternative To Fev1% in

- Copd Diagnosis? *J Evid Based Med Healthc.* 2018;5(26):1964–9.
52. Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, et al. Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. *Chronic Obstr Pulm Dis (Miami, Fla).* 2022;9(2):111–21.
 53. Sorscher S, Abudagga A, Almashat S, Carome MA, Wolfe SM. Placebo-only-controlled versus active-controlled trials of new drugs for nine common life-threatening diseases. *Open Access J Clin Trials.* 2018;10:19–28.
 54. Anzueto A, Kaplan A. Dual bronchodilators in chronic obstructive pulmonary disease: Evidence from randomized controlled trials and real-world studies. *Respir Med X.* 2020;2:100016. Available from: <https://www.sciencedirect.com/science/article/pii/S2590143520300038>
 55. Wang Z, Wang C, Yang X. Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease. *Exp Ther Med.* 2018;15(2):1538–45.
 56. Sinulingga TSN, Pandia P, Tarigan AP, Eyanoe PC. The Effect of Long-Acting Beta-2 Agonist Monotherapy and Long-Acting Anticholinergic Monotherapy to Quality-of-Life in Group B Stable COPD Patients. *J Respirologi Indones.* 2022;42(4):2–6.
 57. Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. *Respir Res.* 2019;20(1):238.
 58. Blair HA. Tiotropium/Olodaterol: A Review in COPD. *Drugs.* 2019;79(9):997–1008.
 59. Tanimura K, Sato S, Fujita Y, Yamamoto Y, Hajiro T, Horita N, et al. The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Chron Respir Dis.* 2023;20:14799731231166008.
 60. Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S. Evidence-

- based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. *Int J Chron Obstruct Pulmon Dis.* 2019;14:1251–65.
61. Papi A, Fabbri LM, Kerstjens HAM, Rogliani P, Watz H, Singh D. Inhaled long-acting muscarinic antagonists in asthma - A narrative review. *Eur J Intern Med.* 2021;85:14–22.
 62. Rhyou H-I, Nam Y-H. Predictive factors of response to inhaled corticosteroids in newly diagnosed asthma: A real-world observational study. *Ann allergy, asthma Immunol Off Publ Am Coll Allergy, Asthma, Immunol.* 2020;125(2):177–81.
 63. Cheng S-L. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis.* 2018;13:2775–84.
 64. Mathioudakis AG, Bikov A, Foden P, Lahousse L, Brusselle G, Singh D, et al. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. *Eur Respir J.* 2020;55(5).
 65. Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: Focus on symptoms and exacerbations. *Respir Med.* 2020;166:105938.
 66. Branson RD. Oxygen Therapy in COPD. *Respir Care.* 2018;63(6):734–48.
 67. Lacasse Y, Tan A-YM, Maltais F, Krishnan JA. Home Oxygen in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med.* 2018;197(10):1254–64.
 68. Mete B, Pehlivan E, Gülbaş G, Günen H. Prevalence of malnutrition in COPD and its relationship with the parameters related to disease severity. *Int J Chron Obstruct Pulmon Dis.* 2018;13:3307–12.
 69. Simon S, Joean O, Welte T, Rademacher J. The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus. *Eur Respir Rev an Off J Eur Respir Soc.* 2023;32(169).
 70. Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). *Cochrane database Syst Rev.*

- 2018;6(6):CD002733.
71. Ignatova GL, Avdeev SN, Antonov VN. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study. *Sci Rep.* 2021;11(1):15948.
 72. Shin K-C. Physical activity in chronic obstructive pulmonary disease: clinical impact and risk factors. *Korean J Intern Med.* 2018;33(1):75–7.
 73. Welch J, Kipp S, Sheel A. Respiratory muscles during exercise: mechanics, energetics, and fatigue. *Curr Opin Physiol.* 2019;10.
 74. Shei R-J. Recent Advancements in Our Understanding of the Ergogenic Effect of Respiratory Muscle Training in Healthy Humans: A Systematic Review. *J strength Cond Res.* 2018;32(9):2665–76.
 75. Wouters EFM, Wouters BBREF, Augustin IML, Houben-Wilke S, Vanfleteren LEGW, Franssen FME. Personalised pulmonary rehabilitation in COPD. *Eur Respir Rev an Off J Eur Respir Soc.* 2018;27(147).
 76. Gea J, Pascual S, Casadevall C, Orozco-Levi M, Barreiro E. Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings. *J Thorac Dis.* 2015;7(10):E418-38.
 77. Hill C, Lazzeri M, Abrosca F. Breathing exercise and mucus clearance techniques in pulmonary rehabilitation. In: Clini E, Holland A, Pitta F, editors. *Textbook of pulmonary rehabilitation.* 1st ed. Los Angeles: Springer; 2018. p. 205–17.
 78. Chinese Health Qigong Association. *Chinese health Qigong—Liu Zi Jue.* 2nd ed. Beijing: Foreign Press; 2007. 1–70 p.
 79. Xia J, Pei S, Chen Z, Wang L, Hu J, Wang J. Effects of Conventional Speech Therapy with Liuzijue Qigong, a Traditional Chinese Method of Breath Training, in 70 Patients with Post-Stroke Spastic Dysarthria. *Med Sci Monit Int Med J Exp Clin Res.* 2023;29:e939623.
 80. Williams N. The Borg Rating of Perceived Exertion (RPE) scale. *Occup Med (Chic Ill).* 2017;67(5):404–5. Available from: <https://doi.org/10.1093/occmed/kqx063>
 81. Jakobsen MD, Sundstrup E, Persson R, Andersen CH, Andersen LL. Is

- Borg's perceived exertion scale a useful indicator of muscular and cardiovascular load in blue-collar workers with lifting tasks? A cross-sectional workplace study. *Eur J Appl Physiol.* 2014;114(2):425–34.
82. Kammin EJ. The 6-Minute Walk Test: Indications and Guidelines for Use in Outpatient Practices. *J Nurse Pract.* 2022;18(6):608–10.
83. Li P, Liu J, Lu Y, Liu X, Wang Z, Wu W. Effects of long-term home-based Liuzijue exercise combined with clinical guidance in elderly patients with chronic obstructive pulmonary disease. *Clin Interv Aging.* 2018;13:1391–9.
84. Xiao L, Duan H, Li P, Wu W, Shan C, Liu X. A systematic review and meta-analysis of Liuzijue in stable patients with chronic obstructive pulmonary disease. *BMC Complement Med Ther.* 2020;20(1):308.
85. Liao S, Wang F, Lin Q, Jian F, Li Y, Zhong Q, et al. Effect of sitting and lying Liuzijue exercise for pulmonary rehabilitation in acute exacerbation of chronic obstructive pulmonary disease patients with non-invasive ventilation: a randomized controlled trial. *Ann Palliat Med.* 2021;10(9):9914–26.
86. Shi H, Liu T, Dong C, Zhen K, Wang Y, Liu P, et al. Scientific Evidence of Traditional Chinese Exercise (Qigong) for Chronic Obstructive Pulmonary Disease: An Overview of Systematic Reviews and Meta-Analyses. *Biomed Res Int.* 2022;2022:7728973.
87. Wang X, Pi Y, Chen B, Chen P, Liu Y, Wang R, et al. Effect of traditional Chinese exercise on the quality of life and depression for chronic diseases: a meta-analysis of randomised trials. *Sci Rep.* 2015;5(1):15913. Available from: <https://doi.org/10.1038/srep15913>
88. Tang Y, Jiang J, Shen P, Li M, You H, Liu C, et al. Liuzijue is a promising exercise option for rehabilitating discharged COVID-19 patients. *Medicine (Baltimore).* 2021;100(6):e24564.
89. Zhang Q-L, Ge M, Chen C, Fan F-D, Jin Y, Zhang N, et al. Comparison of Effects of Liuzijue Exercise and Conventional Respiratory Training on Patients after Cardiac Surgery: A Randomized Controlled Trial. *Chin J Integr Med.* 2023;29(7):579–89.

90. Chen X, Li Z, Cai Y. Effect of six-word breath exercise on the inflammatory immune factors and pathogen distribution in asthma patients. *Chinese J Nosocomiology*. 2019;29(15):2280–4. Available from: <http://en.oversea.cnki.net/kcms/detail/detail.aspx?QueryID=41&CurRec=22&dbCode=CJFD&filename=ZHYY201915011&dbname=CJFDTEMP>
91. Hu J, Gao R, Wang Y, Li Y, Wang Y, Wang Z, et al. Effect of Liuzijue on pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: study protocol for a multicenter, non-randomized, prospective study. *BMC Complement Med Ther*. 2022;22(1):296.
92. Xu S, Zhang D, He Q, Ma C, Ye S, Ge L, et al. Efficacy of Liuzijue Qigong in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Complement Ther Med*. 2022;65:102809.
93. Pothirat C, Kiatboonsri S, Chuchottaworn C. Validation of the new COPD assessment test translated into Thai in patients with chronic obstructive pulmonary disease. *BMC Pulm Med*. 2014;14(1):193. Available from: <https://doi.org/10.1186/1471-2466-14-193>
94. Fakharian A, Kharabian S, Karimzadeh S, Farhadi T. Validation of the COPD Assessment Test in Patients with COPD in Iran. *Chronic Obstr Pulm Dis Open Access*. 2017;02.
95. Schweizer ML, Braun BI, Milstone AM. Research Methods in Healthcare Epidemiology and Antimicrobial Stewardship-Quasi-Experimental Designs. *Infect Control Hosp Epidemiol*. 2016;37(10):1135–40.
96. Dimitrov DM, Rumrill PD. Pretest-posttest designs and measurement of change. *Work*. 2003;20(2):159–65.
97. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10(5):447–58.
98. Osman S, Ziegler C, Gibson R, Mahmood R, Moraros J. The Association between Risk Factors and Chronic Obstructive Pulmonary Disease in Canada: A Cross-sectional Study Using the 2014 Canadian Community

- Health Survey. *Int J Prev Med*. 2017;8:86.
99. Kukrety SP, Parekh JD, Bailey KL. Chronic obstructive pulmonary disease and the hallmarks of aging. *Lung India*. 2018;35(4):321–7.
100. Boers E, Barrett M, Su JG, Benjafield A V, Sinha S, Kaye L, et al. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. *JAMA Netw open*. 2023;6(12):e2346598.
101. Han MK, Martinez FJ. Host, Gender, and Early-Life Factors as Risks for Chronic Obstructive Pulmonary Disease. *Clin Chest Med*. 2020;41(3):329–37.
102. World Health Organization. Global Adult Tobacco Survey Indonesia 2021. Fact Sheet Indonesia 2021. 2021;
103. Wang X, Liang Q, Li Z, Li F. Body Composition and COPD: A New Perspective. *Int J Chron Obstruct Pulmon Dis*. 2023;18:79–97.
104. Devasahayam J, LaFreniere K, Naik R. Chronic Emphysema. Treasure Island (FL): Statpearls Publisher; 2024.
105. Gallucci M, Carbonara P, Pacilli AMG, di Palmo E, Ricci G, Nava S. Use of Symptoms Scores, Spirometry, and Other Pulmonary Function Testing for Asthma Monitoring. *Front Pediatr*. 2019;7:54.
106. Gold WM, Koth LL. Pulmonary Function Testing. In: Broaddus VC, Mason RJ, Ernst JD, King TE, Lazarus SC, Murray JF, et al., editors. *Murray and Nadel's Textbook of Respiratory Medicine (Sixth Edition)*. Philadelphia: W.B. Saunders; 2016. p. 407-435.e18. Available from: <https://www.sciencedirect.com/science/article/pii/B9781455733835000257>
107. Carsin A-E, Fuertes E, Schaffner E, Jarvis D, Antó JM, Heinrich J, et al. Restrictive spirometry pattern is associated with low physical activity levels. A population based international study. *Respir Med*. 2019;146:116–23.
108. Sparling JL, Melo MFV. Chapter 05 - Pulmonary Pathophysiology and Lung Mechanics in Anesthesiology. In: Cohen EBT-CCTA, editor. *Cohen's Comprehensive Thoracic Anesthesia*. Philadelphia: Elsevier; 2022. p. 66–87. Available from: <https://www.sciencedirect.com/science/article/pii/B9780323713016000056>

109. Tarigan AP, Ananda FR, Pandia P, Sinaga BYM, Maryaningsih M, Agriani A. The impact of upper limb training with breathing maneuver in lung function, functional capacity, dyspnea scale and quality of life in patient with stable chronic obstructive of lung disease. *Maced J Med Sci.* 2019;7(4):567-572.
110. Chang W, Lin HC, Liu HE, Han CY. The Effectiveness of Home-Based Inspiratory Muscle Training on Small Airway Function and Disease-Associated Symptoms in Patients with Chronic Obstructive Pulmonary Disease. *Healthcare.* 2023;11(2310):1-17
111. Shafiq I, Uzbek MH, Zoumot Z, Abuzakouk M, Parappurath N, Wahla AS. Correlation between Reduced FEF25-75% and a Positive Methacholine Challenge Test in Adults with Nonobstructive Baseline Spirometry. *Pulm Med.* 2021;2021:5–9.
112. Malerba M, Radaeli A, Olivini A, Damiani G, Ragnoli B, Sorbello V, et al. Association of FEF25-75% Impairment with Bronchial Hyperresponsiveness and Airway Inflammation in Subjects with Asthma-Like Symptoms. *Respiration.* 2016;91(3):206–14.
113. Kwon DS, Choi YJ, Kim TH, Byun MK, Cho JH, Kim HJ, et al. FEF25-75% values in patients with normal lung function can predict the development of chronic obstructive pulmonary disease. *Int J COPD.* 2020;15:2913–21.
114. Wu S, Zheng C, Liu N, Deng T, Wang J, Qi L, et al. Liuzijue training improves hypertension and modulates gut microbiota profile. *Front Cardiovasc Med.* 2023;10(7).
115. Ting-Ting L, Meng-Jie L, Hui-Ping W, Yan-Qiu H, Chang-De J. Efficacy of Liuzijue respiratory exercise in patients with chronic obstructive pulmonary disease: a meta-analysis. *TMR Non-Drug Ther.* 2018;1(3):75.
116. Chan AWK, Lee A, Lee DTF, Suen LKP, Tam WWS, Chair SY, et al. The sustaining effects of Tai chi Qigong on physiological health for COPD patients: A randomized controlled trial. *Complement Ther Med.* 2013;21(6):585–94. Available from: <https://www.sciencedirect.com/science/article/pii/S0965229913001660>

117. Agustin M, Chang H, Unterborn J, Andoh-Duku A. Correlation of Self-Reported Breathlessness with Post Exercise Dyspnea in Obesity. *Open J Respir Dis.* 2017;07:141–9.
118. McKeough ZJ, Velloso M, Lima VP, et al. Upper limb exercise training for COPD (Review) *Cochrane Database of Systematic Reviews.* 2016;11(4):1-5.
119. Zanchet RC, Viegas CA, Lima T. Efficacy of pulmonary rehabilitation: exercise capacity, respiratory muscle strength and quality of life in patients with chronic obstructive pulmonary disease. *Jornal Brasileiro de Pneumologia.* 2005;31(2):118–24.
120. American Thoracic Society. ATS Statement: Guidelines for the Six-Minute Walk Test. *Am J Respir Crit Care Med.* 2002;166(1):111–7. Available from: <https://doi.org/10.1164/ajrccm.166.1.at1102>
121. Jenkins S, Čečins N. Six-minute walk test: observed adverse events and oxygen desaturation in a large cohort of patients with chronic lung disease. *Intern Med J.* 2011;41(5):416–22.
122. Chetta A, Zanini A, Pisi G, Aiello M, Tzani P, Neri M, et al. Reference values for the 6-min walk test in healthy subjects 20–50 years old. *Respir Med.* 2006;100(9):1573–8. Available from: <https://www.sciencedirect.com/science/article/pii/S0954611106000060>
123. Casanova C, Celli BR, Barria P, Casas A, Cote C, Torres JP de, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. *Eur Respir J.* 2011;37(1):150 LP – 156. Available from: <http://erj.ersjournals.com/content/37/1/150.abstract>
124. Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. *Eur Respir J.* 2014;44(4):873–84.
125. Kwon N, Amin M, Hui DS, Jung K-S, Lim SY, Ta HD, et al. Validity of the COPD assessment test translated into local languages for Asian patients. *Chest.* 2013;143(3):703–10.
126. Khan JH, Lababidi HMS, Al-Moamary MS, Zeitouni MO, AL-Jahdali HH, Al-Amoudi OS, et al. The Saudi guidelines for the diagnosis and

management of COPD. *Ann Thorac Med.* 2014;9(2):55–76.

127. He J. The effect of “Liu Zi Jue” breathing method in the treatment of stable COPD and its influence on T lymphocyte subsets. Beijing University; 2016.

